Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.

Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH.

JAMA Oncol. 2016 Aug 1;2(8):1030-7. doi: 10.1001/jamaoncol.2016.1726.

PMID:
27348762
2.

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.

van der Noll R, Smit WM, Wymenga AN, Boss DS, Grob M, Huitema AD, Rosing H, Tibben MM, Keessen M, Rehorst H, Beijnen JH, Schellens JH.

Invest New Drugs. 2015 Dec;33(6):1197-205. doi: 10.1007/s10637-015-0281-z. Epub 2015 Sep 11.

3.

End-stage cardiomyopathy because of hereditary hemochromatosis successfully treated with erythrocytapheresis in combination with left ventricular assist device support.

Rombout-Sestrienkova E, De Jonge N, Martinakova K, Klöpping C, van Galen KP, Vink A, Wajon EM, Smit WM, van Bree C, Koek GH.

Circ Heart Fail. 2014 May;7(3):541-3. doi: 10.1161/CIRCHEARTFAILURE.114.001198. No abstract available.

PMID:
24847131
4.

Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer.

Helgason HH, Koolen SL, Werkhoven Ev, Malingre MM, Kruijtzer CM, Huitema AD, Schot ME, Smit WM, Beijnen JH, Schellens JH.

Curr Clin Pharmacol. 2014 May;9(2):139-47.

PMID:
24219005
5.

Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).

Thielen N, van der Holt B, Cornelissen JJ, Verhoef GE, Gussinklo T, Biemond BJ, Daenen SM, Deenik W, van Marwijk Kooy R, Petersen E, Smit WM, Valk PJ, Ossenkoppele GJ, Janssen JJ.

Eur J Cancer. 2013 Oct;49(15):3242-6. doi: 10.1016/j.ejca.2013.06.018. Epub 2013 Jul 19.

6.

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.

Thielen N, van der Holt B, Verhoef GE, Ammerlaan RA, Sonneveld P, Janssen JJ, Deenik W, Falkenburg JH, Kersten MJ, Sinnige HA, Schipperus M, Schattenberg A, van Marwijk Kooy R, Smit WM, Chu IW, Valk PJ, Ossenkoppele GJ, Cornelissen JJ.

Ann Hematol. 2013 Aug;92(8):1049-56. doi: 10.1007/s00277-013-1730-4. Epub 2013 Apr 10.

PMID:
23572137
7.

Raynaud-like phenomenon in two patients on nilotinib.

Hazenberg CL, Ossenkoppele GJ, Smit WM.

Br J Haematol. 2012 Aug;158(4):431. doi: 10.1111/j.1365-2141.2012.09215.x. Epub 2012 Jul 5. No abstract available.

PMID:
22765239
8.

A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.

Reyners AK, de Munck L, Erdkamp FL, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga AN, Polee M, Hollema H, van Vugt MA, Schaapveld M, Willemse PH; DoCaCel Study Group.

Ann Oncol. 2012 Nov;23(11):2896-902. doi: 10.1093/annonc/mds107. Epub 2012 Jun 11.

PMID:
22689176
9.

Determinants of engagement in face-to-face and online patient support groups.

Van Uden-Kraan CF, Drossaert CH, Taal E, Smit WM, Bernelot Moens HJ, Van de Laar MA.

J Med Internet Res. 2011 Dec 7;13(4):e106. doi: 10.2196/jmir.1718.

10.

Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.

Hamberg P, Bos MM, Braun HJ, Stouthard JM, van Deijk GA, Erdkamp FL, van der Stelt-Frissen IN, Bontenbal M, Creemers GJ, Portielje JE, Pruijt JF, Loosveld OJ, Smit WM, Muller EW, Schmitz PI, Seynaeve C, Klijn JG; Dutch Breast Cancer Trialists' Group (BOOG).

Clin Breast Cancer. 2011 Apr;11(2):103-13. doi: 10.1016/j.clbc.2011.03.003. Epub 2011 Apr 11.

PMID:
21569996
11.

Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel.

Schröder CP, de Munck L, Westermann AM, Smit WM, Creemers GJ, de Graaf H, Stouthard JM, van Deijk G, Erjavec Z, van Bochove A, Vader W, Willemse PH.

Eur J Cancer. 2011 Jun;47(9):1355-62. doi: 10.1016/j.ejca.2010.12.018. Epub 2011 Jan 19.

PMID:
21251813
12.

Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.

Kroep JR, Linn SC, Boven E, Bloemendal HJ, Baas J, Mandjes IA, van den Bosch J, Smit WM, de Graaf H, Schröder CP, Vermeulen GJ, Hop WC, Nortier JW.

Neth J Med. 2010 Sep;68(9):371-6.

13.

Experiences and attitudes of Dutch rheumatologists and oncologists with regard to their patients' health-related Internet use.

van Uden-Kraan CF, Drossaert CH, Taal E, Smit WM, Seydel ER, van de Laar MA.

Clin Rheumatol. 2010 Nov;29(11):1229-36. doi: 10.1007/s10067-010-1435-1. Epub 2010 Apr 11.

14.

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia.

Deenik W, Janssen JJ, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Daenen SM, Verdonck LF, Ferrant A, Schattenberg AV, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Beverloo HB, Löwenberg B, Valk PJ, Ossenkoppele GJ, Cornelissen JJ.

Haematologica. 2010 Jun;95(6):914-21. doi: 10.3324/haematol.2009.016766. Epub 2009 Dec 16.

15.

[Patients with a haematological malignancy in intensive care].

van de Ven M, Silderhuis VM, Brouwer RM, Legdeur MC, Smit WM.

Ned Tijdschr Geneeskd. 2009;153:A582. Dutch.

PMID:
19930742
16.

Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.

Koolen SL, Huitema AD, Jansen RS, van Voorthuizen T, Beijnen JH, Smit WM, Schellens JH.

Oncologist. 2009 Sep;14(9):944-8. doi: 10.1634/theoncologist.2009-0111. Epub 2009 Sep 2. Review.

17.

Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.

Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, Spanik S, Wagnerova M, Hirte HW, Kaye S, Johri AR, Oza AM.

J Clin Oncol. 2009 Jul 1;27(19):3097-103. doi: 10.1200/JCO.2008.20.4826. Epub 2009 May 18.

PMID:
19451434
18.

Health-related Internet use by patients with somatic diseases: frequency of use and characteristics of users.

van Uden-Kraan CF, Drossaert CH, Taal E, Smit WM, Moens HJ, Siesling S, Seydel ER, van de Laar MA.

Inform Health Soc Care. 2009 Jan;34(1):18-29. doi: 10.1080/17538150902773272.

PMID:
19306196
19.

Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients.

Nieboer P, de Vries EG, Mulder NH, Rodenhuis S, Bontenbal M, van der Wall E, van Hoesel QG, Smit WM, Hupperets P, Voest EE, Nooij MA, Boezen HM, van der Graaf WT.

Bone Marrow Transplant. 2008 Oct;42(7):475-81. doi: 10.1038/bmt.2008.195. Epub 2008 Jul 14.

PMID:
18622420
20.

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.

Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AV, Janssen JJ, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Westveer PH, Beverloo HB, Valk P, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ.

Blood. 2008 Mar 1;111(5):2581-8. doi: 10.1182/blood-2007-08-107482. Epub 2008 Jan 2.

PMID:
18172005
21.

Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.

Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, de Vries EG, Rodenhuis S, van de Vijver MJ.

Br J Cancer. 2006 Nov 20;95(10):1334-41. Epub 2006 Oct 31.

22.

High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study.

Deenik W, van der Holt B, Verhoef GE, Schattenberg AV, Verdonck LF, Daenen SM, Zachée P, Westveer PH, Smit WM, Wittebol S, Schouten HC, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ.

Ann Hematol. 2007 Feb;86(2):117-25. Epub 2006 Oct 10.

PMID:
17031690
23.

Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.

Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH, Schellens JH.

Clin Cancer Res. 2006 Oct 1;12(19):5786-93.

24.

Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma.

Corporaal S, Smit WM, Russel MG, van der Palen J, Boot H, Legdeur MC.

Neth J Med. 2006 May;64(5):141-6.

25.

Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer.

Rodenhuis S, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, van Tinteren H, Peterse JL, van de Vijver MJ, de Vries EG; Netherlands Working Party on Autologous Transplantation in Solid Tumours.

Ann Oncol. 2006 Apr;17(4):588-96. Epub 2006 Jan 30.

PMID:
16446318
26.

Assessing the clinical significance of drug interactions with fluorouracil in patients with colorectal cancer.

Jansman FG, Jansen AJ, Coenen JL, de Graaf JC, Smit WM, Sleijfer DT, Brouwers JR.

Am J Health Syst Pharm. 2005 Sep 1;62(17):1788-93. No abstract available.

PMID:
16120738
27.

Primary allogeneic T-cell responses against mantle cell lymphoma antigen-presenting cells for adoptive immunotherapy after stem cell transplantation.

Hoogendoorn M, Olde Wolbers J, Smit WM, Schaafsma MR, Jedema I, Barge RM, Willemze R, Falkenburg JH.

Clin Cancer Res. 2005 Jul 15;11(14):5310-8.

28.
29.

Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer.

Jansman FG, Idzinga FS, Smit WM, de Graaf JC, Coenen JL, Sleijfer DT, Brouwers JR.

Clin Ther. 2005 Mar;27(3):327-35.

PMID:
15878386
30.

Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas.

Wu KL, Helgason HH, van der Holt B, Wijermans PW, Lokhorst HM, Smit WM, Sonneveld P.

Leukemia. 2005 Jan;19(1):143-5. No abstract available.

PMID:
15510202
31.
32.

[Pregnancy and chemotherapy; an apparent contradiction].

Wobbes MH, de Groot MR, Brons JT, Smit WM.

Ned Tijdschr Geneeskd. 2004 Feb 21;148(8):349-52. Dutch.

PMID:
15032086
33.

Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.

Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.

Biol Blood Marrow Transplant. 2004 Mar;10(3):204-12.

34.
35.

Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval.

Gore ME, Atkinson RJ, Thomas H, Cure H, Rischin D, Beale P, Bougnoux P, Dirix L, Smit WM.

Eur J Cancer. 2002 Dec;38 Suppl 8:S7-12.

PMID:
12645907
36.

A phase II trial of ZD0473 in platinum-pretreated ovarian cancer.

Gore ME, Atkinson RJ, Thomas H, Cure H, Rischin D, Beale P, Bougnoux P, Dirix L, Smit WM.

Eur J Cancer. 2002 Dec;38(18):2416-20.

PMID:
12460786
37.

Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.

Falkenburg JH, Wafelman AR, Joosten P, Smit WM, van Bergen CA, Bongaerts R, Lurvink E, van der Hoorn M, Kluck P, Landegent JE, Kluin-Nelemans HC, Fibbe WE, Willemze R.

Blood. 1999 Aug 15;94(4):1201-8.

PMID:
10438707
38.

Excision of a haemophilic pseudotumour of the ilium, complicated by fistulation.

Heeg M, Smit WM, van der Meer J, van Horn JR.

Haemophilia. 1998 Mar;4(2):132-5.

PMID:
9873852
39.
40.
41.

Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia.

Falkenburg JH, Smit WM, Willemze R.

Immunol Rev. 1997 Jun;157:223-30. Review.

PMID:
9255633
42.

Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells.

Smit WM, Rijnbeek M, van Bergen CA, de Paus RA, Vervenne HA, van de Keur M, Willemze R, Falkenburg JH.

Hum Immunol. 1997 Apr 1;53(2):216-23.

PMID:
9129981
43.

Interleukin-10, interleukin-12, and tumor necrosis factor-alpha differentially influence the proliferation of human CD8+ and CD4+ T-cell clones.

van Bergen CA, Smit WM, van Sluijters DA, Rijnbeek M, Willemze R, Falkenburg JH.

Ann Hematol. 1996 Apr;72(4):245-52.

PMID:
8624379
44.

Relationship between elevated creatine phosphokinase and the clinical spectrum of rhabdomyolysis.

Veenstra J, Smit WM, Krediet RT, Arisz L.

Nephrol Dial Transplant. 1994;9(6):637-41.

PMID:
7970089
45.

Generation of donor-derived antileukemic cytotoxic T-lymphocyte responses for treatment of relapsed leukemia after allogeneic HLA-identical bone marrow transplantation.

Falkenburg JH, Faber LM, van den Elshout M, van Luxemburg-Heijs SA, Hooftman-den Otter A, Smit WM, Voogt PJ, Willemze R.

J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):305-9.

PMID:
8280712
46.

[Leiomyosarcoma of the small intestine: a rare cause of gastrointestinal blood loss].

Ho GH, Smit WM, Haanraadts EJ, ten Velden JJ, Hoitsma HF.

Ned Tijdschr Geneeskd. 1993 Jul 10;137(28):1400-3. Dutch.

PMID:
8345894
47.

Acute retinal necrosis in a renal allograft recipient--an unusual manifestation of cytomegalovirus infection.

Smit WM, Wagemans MA, Jansen CL, vd Horn GJ, Surachno JS.

Transplantation. 1993 Jan;55(1):219-21. No abstract available.

PMID:
8380509
48.

Fulminant falciparum malaria.

Smit WM, Oudemans-van Straaten HM, Zandstra DF.

Intensive Care Med. 1990;16(8):517-9.

PMID:
2286734
49.

Jahn-Teller effect in the emission and excitation spectra of the Sb3+ ion in LPO4 (L=Sc,Lu,Y).

Oomen EW, Smit WM, Blasse G.

Phys Rev B Condens Matter. 1988 Jan 1;37(1):18-26. No abstract available.

PMID:
9943542
50.

Zone melting as an aid to impurity determination by thermal analysis.

van Wijk HF, van der Most PF, Smit WM.

Anal Chim Acta. 1967 May-Jun;38(1):285-90. No abstract available.

PMID:
6045430

Supplemental Content

Support Center